CLOVIS ONCOLOGY Forum: Community User: Maroni

Na dann schauen wir doch mal gespannt, was da am 22.8. passiert :)

Clovis Oncology believes that accelerated approval might be on the cards Published By: Eunice Gettys on August 18, 2016 11:08 am EST Stifel believes that the response by the Federal Drug Authority regarding the new drug application by Clovis Oncology Inc (NASDAQ:CLVS) is very positive and the drug might enter the clinical trial phase sooner than expected. The American drug regulatory authority, namely FDA, is expected to respond regarding Rucaparib on Monday, August 22. According to the analyst, Clovis Oncology has thus far only presented data relating to best case scenarios in which patients with Prothrombin time sensitive disease showed encouraging responses. The data suggests that the positive response rates in these patients were found to be between 60% to 80%. Comparing these results with Olaparib data makes a very strong case in favor of Rucaparib, as the response rate for Olaparib in similar setting was only 46%. The study will, however, include data for Prothrombin resistant patients, the response rates for which are expected to be far lower, but it will be interesting to see if they are still above the Olaparib.   According to the recent comments made by the management, the analyst expects the response rate for platinum resistant BRCA patients to be around 35%, which is still significantly higher than Olaparib. The response rates are expected to vary and will depend on the company’s management that whether they will apply for “2 or higher lines of therapy” or “3 or higher lines of therapy”. Stifel analyst believes that the most important part will be the data regarding the emergence of secondary tumors following the treatment. The data thus far has shown positive results and can be a huge positive for the company. The analyst reaffirmed Buy rating and a price target of $30. The analyst ratings for CLVS have 2 Buy, 1 Outperform and 6 Hold ratings. The stock now trades at a price of $17.05.

Zacks Investment Research upgraded shares of Clovis Oncology Inc. (NASDAQ:CLVS) from a hold rating to a buy rating in a research note released on Thursday morning. Zacks Investment Research currently has $18.00 target price on the biopharmaceutical company’s stock. According to Zacks, “Clovis’ second quarter loss was narrower-than-expected. We are encouraged by the company's progress with its lead pipeline candidate, rucaparib. The company has submitted a rolling NDA for the candidate and is on track to file for EU approval in the fourth quarter of 2016. Approval would be a huge boost for the company given the immense commercial potential in the target market and the demand for PARP inhibitors. However, we remain concerned about Clovis’ dependence on just one candidate. The company has already suffered a huge setback on the regulatory front when it was informed by the FDA that the agency would issue a complete response letter for rociletinib. Based on this, the company decided to discontinue investment in rociletinib. Any further regulatory or pipeline setback would weigh heavily on the stock.”

Angeblich haben die “Baker Brothers Advisors“ jetzt 51.3Million $ an Aktien... Und “Palo Alto Investors“ haben auch aufgestockt..

HealthCor Management, L.P. files portfolio update HealthCor Management, L.P. just filed a portfolio update (also known as a 13-F), dated August 15, 2016. The portfolio holdings are as of June 30, 2016. HealthCor Management, L.P. reported adding to its positions of:Aetna Inc.Clovis OncologyCOLLEGIUM PHARMACEUTICAL, INCConatus PharmaceuticalsEdwards Lifesciences CorporationHealthSouth CorporationPRA Health Sciences, Inc.Neurocrine BiosciencesNatera, Inc.Labor Smart, Inc.ICON plcHumana Inc. Positions in the following companies appear to have been reduced: AkornBristol-Myers Squibb CompanyDex One CorporationHCA HoldingsZimmer HoldingsWaters Corporat ionUniversal Health ServicesThermo Fisher Scientific IncQuest Management Inc.INC Research Holdings, Inc.

Up up....

Formycon weiterhin.. Und ansonsten nur noch kleine Werte, bei denen ich aber bös im Minus bin..

man liesst sich gar nicht mehr?;( wo steckst du noch in Aktien drin?

mit 28 usd könnte ich leben;)

Clovis Oncology Inc. (NASDAQ:CLVS)‘s stock had its “hold” rating restated by JPMorgan Chase & Co. in a research note issued to investors on Tuesday. They currently have a $13.00 target price on the biopharmaceutical company’s stock. JPMorgan Chase & Co.’s target price points to a potential downside of 18.24% from the stock’s previous close. The analysts wrote, “CLVS’ 2Q report this afternoon was fairly uneventful, though the co did note that rucaparib’s full NDA dataset had been accepted for presentation at ESMO (Oct 7- 11, Copenhagen), and that ARIEL3 data (rucap in maintenance) is now expected in 4Q17 following release of a similar data set from TSRO (though CLVS has no knowledge of the event rate in ARIEL3). While we do see potential value for rucap, we think it’s hard to differentiate between the PARPs at this stage, and we are maintaining our Neutral rating.”” A number of hedge funds and institutional investors have bought and sold shares of CLVS. Legal & General Group Plc raised its position in Clovis Oncology by 56.8% in the first quarter. Legal & General Group Plc now owns 8,483 shares of the biopharmaceutical company’s stock valued at $164,000 after buying an additional 3,072 shares in the last quarter. Fox Run Management L.L.C. acquired a new position in Clovis Oncology during the second quarter valued at $154,000. CIBC World Markets Inc. raised its position in Clovis Oncology by 7.8% in the first quarter. CIBC World Markets Inc. now owns 11,680 shares of the biopharmaceutical company’s stock valued at $224,000 after buying an additional 850 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in Clovis Oncology during the first quarter valued at $233,000. Finally, Kazazian Asset Management LLC acquired a new position in Clovis Oncology during the first quarter valued at $282,000. Clovis Oncology (NASDAQ:CLVS) traded down 0.69% on Tuesday, reaching $15.79. The company had a trading volume of 31,344 shares. The stock’s market capitalization is $605.69 million. Clovis Oncology has a 12 month low of $11.57 and a 12 month high of $116.75. The firm has a 50 day moving average price of $14.46 and a 200-day moving average price of $16.35. Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($2.13) by $0.06. During the same period last year, the firm earned ($2.10) EPS. Analysts forecast that Clovis Oncology will post ($8.16) earnings per share for the current fiscal year. A number of other equities research analysts have also recently weighed in on the company. SunTrust Banks Inc. initiated coverage on Clovis Oncology in a report on Friday, August 5th. They set a “buy” rating and a $25.00 price target for the company. Vetr raised Clovis Oncology from a “buy” rating to a “strong-buy” rating and set a $17.71 target price for the company in a research note on Thursday, June 9th. Credit Suisse Group AG reissued a “hold” rating on shares of Clovis Oncology in a research note on Tuesday, July 12th. Piper Jaffray Cos. reissued a “hold” rating and issued a $14.00 target price on shares of Clovis Oncology in a research note on Wednesday, June 29th. Finally, Mizuho lowered their target price on Clovis Oncology from $21.00 to $15.00 and set a “neutral” rating for the company in a research note on Monday, April 11th. Six equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $28.98. Clovis Oncology, Inc (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer.

Clovis Oncology Inc. (NASDAQ:CLVS) has been given an average rating of “Buy” by the twelve brokerages that are currently covering the firm. Five analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $29.86. Shares of Clovis Oncology (NASDAQ:CLVS) opened at 16.87 on Monday. Clovis Oncology has a one year low of $11.57 and a one year high of $116.75. The stock’s 50 day moving average is $14.57 and its 200-day moving average is $16.30. The stock’s market capitalization is $647.12 million.

Schön schön.. Wieder über 15... Hoffentlich nachhaltig!!

Zacks Investment Research upgraded shares ofClovis Oncology Inc. (NASDAQ:CLVS) from a hold rating to a buy rating in a report released on Thursday morning. Zacks Investment Research currently has $18.00 target price on the biopharmaceutical company’s stock. According to Zacks, “Clovis’ second quarter loss was narrower-than-expected. We are encouraged by the company's progress with its lead pipeline candidate, rucaparib. The company has submitted a rolling NDA for the candidate and is on track to file for EU approval in the fourth quarter of 2016. Approval would be a huge boost for the company given the immense commercial potential in the target market and the demand for PARP inhibitors. However, we remain concerned about Clovis’ dependence on just one candidate. The company has already suffered a huge setback on the regulatory front when it was informed by the FDA that the agency would issue a complete response letter for rociletinib. Based on this, the company decided to discontinue investment in rociletinib. Any further regulatory or pipeline setback would weigh heavily on the stock.”

http://www.stockrevealer.com/blog/2016/8/11/vn8kys2t13fddbrejyui0w0092gnyu

Hmmmm sieht eher nach schlechten Zahlen aus momentan

eigtl ein gutes Zeichen. ...das es vorher so anzieht,da wissen leider wiedermal einige mehr